U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H24N2O5
Molecular Weight 396.4372
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BENAZEPRILAT

SMILES

c1ccc(cc1)CC[C@@]([H])(C(=O)O)N[C@@]2([H])CCc3ccccc3N(CC(=O)O)C2=O

InChI

InChIKey=MADRIHWFJGRSBP-ROUUACIJSA-N
InChI=1S/C22H24N2O5/c25-20(26)14-24-19-9-5-4-8-16(19)11-13-17(21(24)27)23-18(22(28)29)12-10-15-6-2-1-3-7-15/h1-9,17-18,23H,10-14H2,(H,25,26)(H,28,29)/t17-,18-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including: https://www.drugs.com/pro/benazepril.html | DOI: 10.1111/j.1527-3466.1990.tb00432.x

Benazepril is a prodrug which is metabolized by the liver into its active form benazeprilat via cleavage of the drug's ester group. Benazepril and Benazeprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals. Benazeprilat has much greater ACE inhibitory activity than does Benazepril. It is indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. Adverse reactions reported in controlled clinical trials and rarer events seen in post-marketing experience, include the following: Stevens-Johnson syndrome, pemphigus, apparent hypersensitivity reactions (manifested by dermatitis, pruritus, or rash), photosensitivity, and flushing, nausea, pancreatitis, constipation, gastritis, vomiting, and melena, thrombocytopenia and hemolytic anemia, anxiety, decreased libido, hypertonia, insomnia, nervousness, and paresthesia. Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Benazepril. Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors (including benazepril) during therapy with lithium.

CNS Activity

Curator's Comment:: Benazepril crossed the blood-brain barrier only to an extremely low extent.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
14.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
LOTENSIN

Approved Use

Amlodipine besylate and benazepril hydrochloride capsules is a combination capsule of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB) and benazepril, an angiotensin converting enzyme (ACE) inhibitor. Amlodipine besylate and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent (1) 1.1 Hypertension Amlodipine besylate and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent.

Launch Date

6.7780798E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
437 pmol/g
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BENAZEPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
334 pmol × h/g
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BENAZEPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.6 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BENAZEPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
n = 116
Health Status: unhealthy
Condition: Essential hypertension
Age Group: adult
Population Size: 116
Sources:
Other AEs: Headache, Back pain...
Other AEs:
Headache (8.6%)
Back pain (2.6%)
Diarrhoea (0.9%)
Upper respiratory tract infection (3.4%)
Peripheral oedema (1.7%)
Sinusitis (1.7%)
Fatigue (0.9%)
Cough (1.7%)
Arthralgia (0.9%)
Sources:
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 193
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 193
Sources:
Other AEs: Headache, Fatigue...
Other AEs:
Headache (9%)
Fatigue (2%)
Nausea (2%)
Dizziness (2%)
Cough increased (2%)
Sources:
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 1145
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 1145
Sources:
Other AEs: Headache, Fatigue...
Other AEs:
Headache (3%)
Fatigue (2%)
Nausea (1%)
Dizziness (3%)
Dizziness postural (1%)
Cough increased (2%)
Sources:
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
n = 771
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 771
Sources:
Other AEs: Headache, Fatigue...
Other AEs:
Headache (3%)
Fatigue (2%)
Nausea (1%)
Dizziness (2%)
Dizziness postural (1%)
Cough increased (1%)
Sources:
5 mg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 184
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 184
Sources:
Other AEs: Headache, Dizziness...
Other AEs:
Headache (6%)
Dizziness (2%)
Dizziness postural (2%)
Sources:
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
unhealthy
n = 86
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 86
Sources:
Other AEs: Headache, Fatigue...
Other AEs:
Headache (2%)
Fatigue (5%)
Nausea (1%)
Cough increased (1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Arthralgia 0.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
n = 116
Health Status: unhealthy
Condition: Essential hypertension
Age Group: adult
Population Size: 116
Sources:
Diarrhoea 0.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
n = 116
Health Status: unhealthy
Condition: Essential hypertension
Age Group: adult
Population Size: 116
Sources:
Fatigue 0.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
n = 116
Health Status: unhealthy
Condition: Essential hypertension
Age Group: adult
Population Size: 116
Sources:
Cough 1.7%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
n = 116
Health Status: unhealthy
Condition: Essential hypertension
Age Group: adult
Population Size: 116
Sources:
Peripheral oedema 1.7%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
n = 116
Health Status: unhealthy
Condition: Essential hypertension
Age Group: adult
Population Size: 116
Sources:
Sinusitis 1.7%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
n = 116
Health Status: unhealthy
Condition: Essential hypertension
Age Group: adult
Population Size: 116
Sources:
Back pain 2.6%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
n = 116
Health Status: unhealthy
Condition: Essential hypertension
Age Group: adult
Population Size: 116
Sources:
Upper respiratory tract infection 3.4%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
n = 116
Health Status: unhealthy
Condition: Essential hypertension
Age Group: adult
Population Size: 116
Sources:
Headache 8.6%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
n = 116
Health Status: unhealthy
Condition: Essential hypertension
Age Group: adult
Population Size: 116
Sources:
Cough increased 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 193
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 193
Sources:
Dizziness 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 193
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 193
Sources:
Fatigue 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 193
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 193
Sources:
Nausea 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 193
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 193
Sources:
Headache 9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 193
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 193
Sources:
Dizziness postural 1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 1145
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 1145
Sources:
Nausea 1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 1145
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 1145
Sources:
Cough increased 2%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 1145
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 1145
Sources:
Fatigue 2%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 1145
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 1145
Sources:
Dizziness 3%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 1145
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 1145
Sources:
Headache 3%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 1145
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 1145
Sources:
Cough increased 1%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
n = 771
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 771
Sources:
Dizziness postural 1%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
n = 771
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 771
Sources:
Nausea 1%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
n = 771
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 771
Sources:
Dizziness 2%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
n = 771
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 771
Sources:
Fatigue 2%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
n = 771
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 771
Sources:
Headache 3%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
n = 771
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 771
Sources:
Dizziness postural 2%
5 mg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 184
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 184
Sources:
Dizziness 2%
5 mg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 184
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 184
Sources:
Headache 6%
5 mg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 184
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 184
Sources:
Cough increased 1%
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
unhealthy
n = 86
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 86
Sources:
Nausea 1%
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
unhealthy
n = 86
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 86
Sources:
Headache 2%
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
unhealthy
n = 86
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 86
Sources:
Fatigue 5%
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
unhealthy
n = 86
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 86
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
PubMed

PubMed

TitleDatePubMed
Sympathomoderating influence of benazepril in essential hypertension.
1992 Apr
Short-term metabolic effects of the ACE-inhibitor benazepril in type 2 diabetes mellitus associated with arterial hypertension.
1992 Jul-Aug
[Serological study on inhibitory function of shenkang injection on glomerular mesangial cell].
2001 Jul
[CEA comprehensive evaluation for Western and traditional Chinese hypotensive drugs].
2001 Sep
Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension.
2002
Effects of benazepril, an angiotensin-converting enzyme inhibitor, combined with CGS 35066, a selective endothelin-converting enzyme inhibitor, on arterial blood pressure in normotensive and spontaneously hypertensive rats.
2002 Aug
[Effects of benazepril on apoptosis in the kidney of diabetic rats].
2002 Jun
[The effects of angiotensin-converting enzyme inhibitor on IgA nephropathy and the influencing factors].
2002 Jun
Combination therapy with benazepril and oral adsorbent ameliorates progressive renal fibrosis in uremic rats.
2002 Mar
[Clinical observation on effect of shenle capsule in treating mesangial proliferating glomerulonephritis].
2002 May
Self-measured systolic blood pressure in the morning is a strong indicator of decline of renal function in hypertensive patients with non-diabetic chronic renal insufficiency.
2002 May
[Non-immunologic factor: immunosuppressive drug-induced nephrotoxicity].
2002 Nov
Optimisation by experimental design of a capillary electrophoretic method for the separation of several inhibitors of angiotensin-converting enzyme using alkylsulphonates.
2002 Nov 29
Effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of benazepril in cats.
2002 Oct
Effects of antihypertensive drugs on peritoneal vessels in hypertensive dogs with mild renal insufficiency.
2003
[The use of angiotensin-converting enzyme inhibitor benazepril in acute period of myocardial infarction].
2003
[Comparative effectiveness of lotensin and capoten in patients with chronic cardiac failure].
2003
Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension.
2003 Apr
Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
2003 Apr
Sialic acid 9-O-acetylesterase catalyzes the hydrolyzing reaction from alacepril to deacetylalacepril.
2003 Aug
Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients.
2003 Aug
Gene expression profile revealed different effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibitor on heart failure.
2003 Dec
[Effect of the compound of traditional Chinese drugs on gene expression of renal endothelin and its receptor of experimental diabetic nephropathy].
2003 Feb
Linear IgA dermatosis induced by a new angiotensin-converting enzyme inhibitor.
2003 Feb
Quantitative determination of benazepril and benazeprilat in human plasma by gas chromatography-mass spectrometry using automated 96-well disk plate solid-phase extraction for sample preparation.
2003 Jan 5
Argyria associated with colloidal silver supplementation.
2003 Jul
The first hypertension trial comparing the effects of two fixed-dose combination therapy regimens on cardiovascular events: Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH).
2003 Jul-Aug
Rationale for combination therapy as initial treatment for hypertension.
2003 Jul-Aug
Using the electronic medical record to enhance the use of combination drugs.
2003 Jul-Aug
An angiotensin converting enzyme inhibitor, benazepril can be transformed to an active metabolite, benazeprilat, by the liver of dogs with ascitic pulmonary heartworm disease.
2003 Jun
Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting.
2003 Jun
[Study on candidate genes of benazepril related cough in Chinese hypertensives].
2003 Jun
Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats.
2003 Jun
Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.
2003 Mar
Correlation of Angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by Angiotensin-converting enzyme inhibitor.
2003 Mar
Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.
2003 Mar
Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients.
2003 Mar
[Postmarketing surveillance of benazepril-related cough and related risk factors analysis on hypertensives].
2003 May
Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches.
2003 May-Jun
Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy.
2003 Nov-Dec
By the way, doctor. After a recent blood pressure check, my doctor bumped up my dose of Lotensin [an ACE inhibitor] from 10 milligrams to 20. I had been taking the 10-mg pill in the morning, but my doctor advised me to take the new, higher dose in the evening. He said most strokes and heart attacks happen in the morning, and that I could get better protection by taking the drug right before. But I read in the Health Letter a couple of months ago that you recommend morning intake, so I am confused.
2003 Oct
[Vasopressin analogue injection as ultimate measure for counteracting severe catecholamine-refractory poisoning by several vasodilators taken with suicidal intent].
2003 Oct 17
Investigation of pimobendan versus benazepril in canine myxomatous valvular disease.
2003 Oct 4
Angiotensin II inhibition increases cellular glucose transport during reperfusion but not ischemia in pig hearts.
2003 Sep
Systemic contact dermatitis due to captopril without cross-sensitivity to fosinopril, quinapril and benazepril.
2004
Effects of co-administration of urokinase and benazepril on severe IgA nephropathy.
2004 Apr
Hypertensive patients from two rural Chinese counties respond differently to benazepril: the Anhui Hypertension Health Care Study.
2004 Feb
Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress.
2004 Feb
Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis.
2004 Feb
Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass.
2004 Jan
Patents

Sample Use Guides

The recommended initial dose for patients not receiving a diuretic is 10 mg once a day. The usual maintenance dosage range is 20-40 mg per day administered as a single dose or in two equally divided doses. A dose of 80 mg gives an increased response, but experience with this dose is limited.
Route of Administration: Oral
In Vitro Use Guide
Benazepril inhibited both adrenaline-stimulated aortic PGI2 synthesis (25 pg mg -1 min-1) and carbachol-stimulated urinary bladder PGI2 synthesis (20 pg mg -1 min-1) in dose-dependent manners. IC50 (concentrations of antagonist at which agonist-stimulated PGI2 synthesis was inhibited by 50%) was 8 x 10-5.
Name Type Language
BENAZEPRILAT
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
BENAZEPRIL RELATED COMPOUND C [USP]
Common Name English
BENAZEPRILAT [USAN]
Common Name English
BENAZEPRILAT [INN]
Common Name English
1H-1-BENZAZEPINE-1-ACETIC ACID, 3-((1-CARBOXY-3-PHENYLPROPYL)AMINO)-2,3,4,5-TETRAHYDRO-2-OXO-, (S-(R*,R*))-
Common Name English
CGS-14831
Code English
BENAZEPRIL HYDROCHLORIDE IMPURITY C [EP]
Common Name English
BENAZEPRIL DIACID
MI  
Common Name English
BENAZEPRILAT [WHO-DD]
Common Name English
BENAZEPRIL RELATED COMPOUND C
USP   USP-RS  
Common Name English
BENAZEPRIL DIACID [MI]
Common Name English
CGS 14831
Code English
(3S)-3-(((1S)-1-CARBOXY-3-PHENYLPROPYL)AMINO)-2,3,4,5-TETRAHYDRO-2-OXO-1H-1-BENZAZEPINE-1-ACETIC ACID
Systematic Name English
BENAZEPRIL RELATED COMPOUND C [USP-RS]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175562
Created by admin on Sat Jun 26 08:27:08 UTC 2021 , Edited by admin on Sat Jun 26 08:27:08 UTC 2021
NCI_THESAURUS C247
Created by admin on Sat Jun 26 08:27:08 UTC 2021 , Edited by admin on Sat Jun 26 08:27:08 UTC 2021
Code System Code Type Description
IUPHAR
6375
Created by admin on Sat Jun 26 08:27:08 UTC 2021 , Edited by admin on Sat Jun 26 08:27:08 UTC 2021
PRIMARY
NDF-RT
N0000178477
Created by admin on Sat Jun 26 08:27:08 UTC 2021 , Edited by admin on Sat Jun 26 08:27:08 UTC 2021
PRIMARY Decreased Blood Pressure [PE]
USP_CATALOG
1048641
Created by admin on Sat Jun 26 08:27:08 UTC 2021 , Edited by admin on Sat Jun 26 08:27:08 UTC 2021
PRIMARY USP-RS
INN
6128
Created by admin on Sat Jun 26 08:27:08 UTC 2021 , Edited by admin on Sat Jun 26 08:27:08 UTC 2021
PRIMARY
MERCK INDEX
M2303
Created by admin on Sat Jun 26 08:27:08 UTC 2021 , Edited by admin on Sat Jun 26 08:27:08 UTC 2021
PRIMARY Merck Index
EVMPD
SUB05701MIG
Created by admin on Sat Jun 26 08:27:08 UTC 2021 , Edited by admin on Sat Jun 26 08:27:08 UTC 2021
PRIMARY
NCI_THESAURUS
C72907
Created by admin on Sat Jun 26 08:27:08 UTC 2021 , Edited by admin on Sat Jun 26 08:27:08 UTC 2021
PRIMARY
DRUG BANK
DB14125
Created by admin on Sat Jun 26 08:27:08 UTC 2021 , Edited by admin on Sat Jun 26 08:27:08 UTC 2021
PRIMARY
FDA UNII
JRM708L703
Created by admin on Sat Jun 26 08:27:08 UTC 2021 , Edited by admin on Sat Jun 26 08:27:08 UTC 2021
PRIMARY
PUBCHEM
5463984
Created by admin on Sat Jun 26 08:27:08 UTC 2021 , Edited by admin on Sat Jun 26 08:27:08 UTC 2021
PRIMARY
RXCUI
1546196
Created by admin on Sat Jun 26 08:27:08 UTC 2021 , Edited by admin on Sat Jun 26 08:27:08 UTC 2021
PRIMARY RxNorm
CAS
86541-78-8
Created by admin on Sat Jun 26 08:27:08 UTC 2021 , Edited by admin on Sat Jun 26 08:27:08 UTC 2021
PRIMARY
ChEMBL
CHEMBL1192519
Created by admin on Sat Jun 26 08:27:08 UTC 2021 , Edited by admin on Sat Jun 26 08:27:08 UTC 2021
PRIMARY